Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.

Giacomo Boffa Caterina LapucciE SbragiaR VaraldoA M RaiolaD CurròL RoccatagliataE CapelloA LaroniM MikulskaF GualandiA UccelliE AngelucciG L MancardiM Inglese

Published in: European journal of neurology (2020)

Alemtuzumab and aHSCT are effective treatment choices for aggressive multiple sclerosis. aHSCT seems to be superior to alemtuzumab in inducing complete disease control and in promoting short-term disability improvement.

Keyphrases

multiple sclerosis
stem cell transplantation
high dose
white matter
bone marrow
replacement therapy